Heteroaryl substituted aminopyridine compounds

US10294229B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Daniel S. Gardner · Furlong, US
• Joseph B. Santella · Springfield, US
• Venkatram Reddy Paidi · Bengaluru, IN
• Hong Wu · Meekrap-oord, CN
• John V. Duncia · Newtown, US
• Satheesh Kesavan Nair · Kanchinakote, IN
• John Hynes · Washington Crossing, US
• Xiao Zhu · Winchester, US

Key dates

• Filing date: Jun 23, 2016
• Grant date: May 21, 2019
• Expiry date: Jun 23, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are compounds of Formula (I) or salts thereof, wherein HET is a heteroaryl selected from pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3 d]pyrimidinyl, pyrazolo[3,4 b]pyridinyl, pyrazolo[3,4 d]pyrimidinyl, imidazolo[4,5 b]pyridinyl, and imidazolo[4,5 d]pyrimidinyl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a nitrogen ring atom in said heteroaryl and wherein said heteroaryl is substituted with zero to 2 Rb; A is pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxadiazolyl or dihydroisoxazolyl, each substituted with zero or 1 Ra; and R3, Ra, and Rb are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.